arrow
E

Eva Lonn

mcmaster university
H指数:82
被引数:3.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Atrial fibrillation and atherosclerosis cause different vascular brain lesions on magnetic resonance imaging

房颤和动脉粥样硬化导致磁共振成像上不同的血管性脑损伤。

2025-08-012
PRE
Characteristics, management, and outcomes in women and men with congestive heart failure in 40 countries at different economic levels: an analysis from the Global Congestive Heart Failure (G-CHF) registry

40个国家不同经济水平的女性和男性充血性心力衰竭的特征、管理和结果: 来自全球充血性心力衰竭 (g-chf) 登记处的分析

2024-03-016
OAAI
Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial
2022-12-0137
OA
The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial
2022-08-249
PRE
Racial and Ethnic Differences in the Association Between Classical Cardiovascular Risk Factors and Common Carotid Intima-Media Thickness: An Individual Participant Data Meta-Analysis

经典心血管危险因素与颈总动脉内膜中层厚度之间关系的种族和民族差异: 个体参与者数据荟萃分析

2022-08-0215
OAAI
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial

慢性冠状动脉或外周动脉疾病患者长期使用利伐沙班和阿司匹林联合治疗: COMPASS试验开放标签扩展期间的结果

2022-04-0618
OA
Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk

高心血管风险的糖尿病和非糖尿病个体的运动频率与肾脏和心血管结局之间的关联

2022-01-2016
OAAI
Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis
LANCET
IF88.5
2021-09-0195
PRE
Society Guidelines 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults
2021-08-01501
OAAI
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
2021-05-0818
OAAI
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline The COMPASS MRI Substudy
STROKE
IF8.9
2020-10-0117
OAAI
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients
2020-08-18300
OAAI